Aprepitant
- Generic Name
- Aprepitant
- Brand Names
- Aponvie, Cinvanti, Emend
- Drug Type
- Small Molecule
- Chemical Formula
- C23H21F7N4O3
- CAS Number
- 170729-80-3
- Unique Ingredient Identifier
- 1NF15YR6UY
- Background
Aprepitant, an antiemetic, is a substance P/neurokinin 1 (NK1) receptor antagonist which, in combination with other antiemetic agents, is indicated for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy. Aprepitant is a selective high-affinity antagonist of human substan...
- Indication
For the prevention of nausea and vomiting associated with highly emetogenic cancer chemotherapy, including high-dose cisplatin (in combination with other antiemetic agents).
- Associated Conditions
- Chemotherapy-Induced Nausea and Vomiting, Post Operative Nausea and Vomiting (PONV), Acute delayed Nausea caused by highly emetogenic cancer chemotherapy
- Associated Therapies
- -
Treatment of Patients With Major Depressive Disorder With MK0869 (0869-060)(COMPLETED)
Phase 3
Completed
- Conditions
- First Posted Date
- 2002-05-03
- Last Posted Date
- 2015-02-09
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 450
- Registration Number
- NCT00035282
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath